Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin-related compounds.
In a statement, Philip Young, CEO of Lobe Sciences said: "Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule."
"The company is actively pursuing drug development programs using two initial proprietary psilocin analogues. L-130, targeting neurologic conditions such as severe anxiety, Post Traumatic Stress Disorder (PTSD), as well as other brain traumas. L-131, a second new chemical entity related to psilocin and covered in the recently filed patent application is a drug candidate for a second neurological disorder affecting children," he added.
READ: Lobe Sciences updates investors on its regulatory and clinical development plans for its novel synthetic psilocin analogues L-130 and L-131
Lobe is focused on delivering a patient-friendly treatment plan focused on delivering its therapeutics at patients' homes, in their physician's offices, or in the emergency department in a local hospital setting.
Delivering a non-hallucinatory dose of its proprietary compounds over several days should enable patients and their personal doctors the opportunity to maintain their normal routine while receiving treatment, allowing significantly more people access to this new therapeutic approach.
Lobe Sciences is a life sciences company focused on psychedelic medicines. Through collaborations with industry-leading partners, it is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
Contact the author at jon.hopkins@proactiveinvestors.com